These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37567840)

  • 21. Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis.
    Fukunaga A; Takata K; Itoh S; Yamauchi R; Tanaka T; Yokoyama K; Shakado S; Kohashi K; Yoshizumi T; Hirai F
    Clin J Gastroenterol; 2023 Apr; 16(2):224-228. PubMed ID: 36495383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
    Hayakawa Y; Tsuchiya K; Kurosaki M; Yasui Y; Kaneko S; Tanaka Y; Ishido S; Inada K; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Izumi N
    Invest New Drugs; 2022 Apr; 40(2):392-402. PubMed ID: 34586531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma.
    Kuzuya T; Kawabe N; Hashimoto S; Miyahara R; Sawaki A; Nakano T; Nakaoka K; Tanaka H; Miyachi Y; Mii A; Kamejima S; Takahara T; Kato Y; Sugioka A; Hirooka Y
    Oncology; 2022; 100(1):12-21. PubMed ID: 34731863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymyalgia rheumatica during combination therapy with atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.
    Dosoden N; Kuzuya T; Ito Y; Nishino J; Ohno E; Kawabe N; Hashimoto S; Hirooka Y; Yasuoka H
    Clin J Gastroenterol; 2023 Aug; 16(4):567-571. PubMed ID: 37071371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.
    Takeuchi Y; Nouso K; Fujioka SI; Kariyama K; Kobashi H; Uematsu S; Moriya A; Hagihara H; Takabatake H; Nakamura S; Yabushita K; Kikuchi T; Oyama A; Adachi T; Wada N; Onishi H; Shiraha H; Takaki A
    Cancer Med; 2023 Sep; 12(17):17559-17568. PubMed ID: 37537956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
    Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
    World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report.
    Uchida K; Ozono Y; Uchiyama N; Hatada H; Nakamura K; Komaki Y; Iwakiri H; Hasuike S; Nagata K; Sato Y; Kawakami H
    Medicine (Baltimore); 2022 Sep; 101(35):e30486. PubMed ID: 36107543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atezolizumab-associated myositis in a patient with unresectable hepatocellular carcinoma.
    Baigi T; Brown EN; De La Torre RM; Abu-Shahin FI
    J Oncol Pharm Pract; 2023 Oct; 29(7):1757-1761. PubMed ID: 37282559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
    N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
    Fukushima T; Morimoto M; Kobayashi S; Ueno M; Uojima H; Hidaka H; Kusano C; Chuma M; Numata K; Tsuruya K; Arase Y; Kagawa T; Hattori N; Ikeda H; Watanabe T; Tanaka K; Maeda S
    Oncologist; 2023 Jul; 28(7):e526-e533. PubMed ID: 37023703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Case of Transverse Myelitis Following Treatment with Atezolizumab for Advanced Hepatocellular Carcinoma.
    Kim KH; Baek YH; Kang YW; Yoon BA; Moon SY
    Korean J Gastroenterol; 2023 Jul; 82(1):35-39. PubMed ID: 37489081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
    Casak SJ; Donoghue M; Fashoyin-Aje L; Jiang X; Rodriguez L; Shen YL; Xu Y; Jiang X; Liu J; Zhao H; Pierce WF; Mehta S; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
    Clin Cancer Res; 2021 Apr; 27(7):1836-1841. PubMed ID: 33139264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.
    Komatsu S; Fujishima Y; Kido M; Kuramitsu K; Goto T; Yanagimoto H; Toyama H; Fukumoto T
    BMC Gastroenterol; 2021 Dec; 21(1):470. PubMed ID: 34911458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A Case of Multiple Postoperative Recurrence of Hepatocellular Carcinoma Successfully Treated with Atezolizumab plus Bevacizumab].
    Fujii J; Shinke G; Takeda Y; Ohmura Y; Katsura Y; Kinoshita M; Aoyama S; Kihara Y; Katsuyama S; Ikeshima R; Hiraki M; Sugimura K; Masuzawa T; Hata T; Murata K
    Gan To Kagaku Ryoho; 2023 Jan; 50(1):96-98. PubMed ID: 36759998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports.
    Al Zahrani A; Alfakeeh A
    J Med Case Rep; 2021 Mar; 15(1):132. PubMed ID: 33722275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients.
    Chen YH; Chen YY; Wang JH; Hung CH
    Anticancer Res; 2023 Mar; 43(3):1377-1384. PubMed ID: 36854513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
    Nakagawa M; Inoue M; Ogasawara S; Maruta S; Okubo T; Itokawa N; Iino Y; Obu M; Haga Y; Seki A; Kikuchi Y; Kogure T; Yumita S; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Fujita N; Sakuma T; Kojima R; Kanzaki H; Koroki K; Taida T; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Atsukawa M; Koma Y; Azemoto R; Ito K; Mizumoto H; Shinozaki M; Kato J; Kato N
    Cancer; 2023 Feb; 129(4):590-599. PubMed ID: 36426410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolated Adrenocorticotropic Hormone Deficiency Associated with Atezolizumab and Bevacizumab Administration for Treating Hepatocellular Carcinoma: A Case Series.
    Ikeda Y; Sato S; Omu R; Nishimura A; Arii S; Uchida R; Nomura K; Sato S; Murata A; Shimada Y; Genda T
    Intern Med; 2023 Nov; 62(22):3341-3346. PubMed ID: 37032085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atezolizumab-induced encephalitis in a patient with metastatic breast cancer: a case report and review of neurological adverse events associated with checkpoint inhibitors.
    Nader R; Tannoury E; Rizk T; Ghanem H
    Autops Case Rep; 2021 Apr; 11():e2021261. PubMed ID: 33968830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.